Altana Pulls EU Application For Daxas
This article was originally published in The Pink Sheet Daily
Executive Summary
Altana has withdrawn the European marketing authorization application for its pulmonary agent Daxas (roflumilast), the firm announced Nov. 15
You may also be interested in...
Pfizer Curtails Development Deals For Pulmonary Drug, HIV Therapy
Altana says it will continue to develop Daxas for chronic obstructive pulmonary disease and asthma independently after Pfizer pulls out of the collaboration. One-year data failed to meet one primary endpoint. Pfizer also ends a development pact with Shionogi for the HIV/AIDS agent capravirine.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.